Clinical Trial Update: Evaluation of Enzastaurin in the Treatment of Persistent or Recurrent Ovarian or Primary Peritoneal Cancer [Phase 2]

View source ↗

Summary

Phase 2 clinical trial evaluating enzastaurin for persistent or recurrent ovarian or primary peritoneal cancer has completed with results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Carcinoma
• Ovarian Cancer
• Peritoneal Cancer

Drugs mentioned

• Enzastaurin (enzastaurin)

Snippet

Sponsor: Eli Lilly and Company | Conditions: Ovarian Cancer, Neoplasms | Phase 2 | Status: COMPLETED | Results posted: 2020-12-19